Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.

Coosemans AN, Baert T, D'Heygere V, Wouters R, DE Laet L, VAN Hoylandt A, Thirion G, Ceusters J, Laenen A, Vandecaveye V, Vergote I.

Anticancer Res. 2019 Nov;39(11):5953-5962. doi: 10.21873/anticanres.13800.

PMID:
31704820
2.

Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors.

Coosemans A, Baert T, Ceusters J, Busschaert P, Landolfo C, Verschuere T, Van Rompuy AS, Vanderstichele A, Froyman W, Neven P, Van Calster B, Vergote I, Timmerman D.

Int J Gynecol Cancer. 2019 Nov;29(9):1381-1388. doi: 10.1136/ijgc-2019-000521.

PMID:
31685557
3.

CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression.

Riva M, Wouters R, Weerasekera A, Belderbos S, Nittner D, Thal DR, Baert T, Giovannoni R, Gsell W, Himmelreich U, Van Ranst M, Coosemans A.

Biol Open. 2019 Sep 12;8(9). pii: bio044552. doi: 10.1242/bio.044552.

4.

Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.

du Bois A, Baert T, Vergote I.

J Clin Oncol. 2019 Sep 20;37(27):2398-2405. doi: 10.1200/JCO.19.00022. Epub 2019 Aug 12. No abstract available.

PMID:
31403864
5.

Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas.

Glorie N, Baert T, VAN DEN Bosch T, Coosemans AN.

Anticancer Res. 2019 Aug;39(8):3981-3989. doi: 10.21873/anticanres.13553. Review.

PMID:
31366479
6.

Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.

Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I, Coosemans A.

Front Immunol. 2019 Jun 4;10:1273. doi: 10.3389/fimmu.2019.01273. eCollection 2019.

7.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO–ESGO Ovarian Cancer Consensus Conference Working Group.

Int J Gynecol Cancer. 2019 May 2. pii: ijgc-2019-000308. doi: 10.1136/ijgc-2019-000308. [Epub ahead of print]

PMID:
31048403
8.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO–ESGO Ovarian Cancer Consensus Conference Working Group.

Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062.

PMID:
31046081
9.

Combining conventional therapy with immunotherapy: A risky business?

Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S, Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I.

Eur J Cancer. 2019 May;113:41-44. doi: 10.1016/j.ejca.2019.02.014. Epub 2019 Apr 6.

PMID:
30965214
10.

Low-grade Serous Ovarian Carcinoma.

Ricciardi E, Baert T, Ataseven B, Heitz F, Prader S, Bommert M, Schneider S, du Bois A, Harter P.

Geburtshilfe Frauenheilkd. 2018 Oct;78(10):972-976. doi: 10.1055/a-0717-5411. Epub 2018 Oct 19.

11.

Differences in physical environmental characteristics between adolescents' actual and shortest cycling routes: a study using a Google Street View-based audit.

Verhoeven H, Van Hecke L, Van Dyck D, Baert T, Van de Weghe N, Clarys P, Deforche B, Van Cauwenberg J.

Int J Health Geogr. 2018 May 29;17(1):16. doi: 10.1186/s12942-018-0136-x.

12.

Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.

Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A.

Gynecol Oncol. 2018 Jul;150(1):31-37. doi: 10.1016/j.ygyno.2018.05.004. Epub 2018 May 9.

PMID:
29751991
13.

Factors related with public open space use among adolescents: a study using GPS and accelerometers.

Van Hecke L, Verhoeven H, Clarys P, Van Dyck D, Van de Weghe N, Baert T, Deforche B, Van Cauwenberg J.

Int J Health Geogr. 2018 Jan 22;17(1):3. doi: 10.1186/s12942-018-0123-2.

14.

Orientation of Preclinical Research in Ovarian Cancer.

Baert T, Garg AD, Agostinis P, Vergote I, Coosemans A.

Int J Gynecol Cancer. 2017 Oct;27(8):1579-1586. doi: 10.1097/IGC.0000000000001053. Review.

PMID:
28945211
15.

Ovarian cancer and the immune system.

Baert T, Vergote I, Coosemans A.

Gynecol Oncol Rep. 2017 Jan 6;19:57-58. doi: 10.1016/j.gore.2017.01.002. eCollection 2017 Feb.

16.

In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol.

Baert T, Garg AD, Vindevogel E, VAN Hoylandt A, Verbist G, Agostinis P, Vergote I, Coosemans AN.

Anticancer Res. 2016 Nov;36(11):5793-5801.

PMID:
27793901
17.

The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer.

Vindevogel E, Baert T, VAN Hoylandt A, Verbist G, Vande Velde G, Garg AD, Agostinis P, Vergote I, Coosemans AN.

Anticancer Res. 2016 Nov;36(11):5781-5792.

PMID:
27793900
18.

Choriocarcinoma in Situ in a Partial Hydatidiform Mole A: Case Report.

Baert T, Vermeesch J, Timmerman D, Vergote I, Moerman P.

J Reprod Med. 2016 Aug;61(7-8):398-402.

PMID:
30408390
19.

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

Coosemans A, Decoene J, Baert T, Laenen A, Kasran A, Verschuere T, Seys S, Vergote I.

Oncoimmunology. 2015 Dec 21;5(4):e1111505. eCollection 2016 Apr.

20.

Ovarian cancer in children and adolescents: A rare disease that needs more attention.

Baert T, Storme N, Van Nieuwenhuysen E, Uyttebroeck A, Van Damme N, Vergote I, Coosemans A.

Maturitas. 2016 Jun;88:3-8. doi: 10.1016/j.maturitas.2016.03.003. Epub 2016 Mar 8. Review.

PMID:
27105689
21.

The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer.

Baert T, Verschuere T, Van Hoylandt A, Gijsbers R, Vergote I, Coosemans A.

J Immunother Cancer. 2015 Dec 15;3:57. doi: 10.1186/s40425-015-0102-0. eCollection 2015.

22.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

23.

A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?

Coosemans A, Baert T, Vergote I.

Facts Views Vis Obgyn. 2015;7(1):73-8.

24.

Immunological parameters as a new lead in the diagnosis of ovarian cancer.

Baert T, Timmerman D, Vergote I, Coosemans A.

Facts Views Vis Obgyn. 2015;7(1):67-72.

Supplemental Content

Support Center